2ⁿᵈ Edition of the Cancer R&D World Conference 2026

The worldwide oncology pipeline is experiencing rapid movement forward due to new and transformative research breakthroughs in molecular biology, immunotherapy, and precision medicine. Drug candidates under development, including next-generation targeted therapies, bispecific antibodies, and cell and gene-based therapies, represent exciting new innovations, further opening the door for an entirely new era of cancer care and management. In addition, new areas of research, such as biomarker research and computational modeling, will improve efficiencies for the oncology pipeline for identification of compounds with the most promising drug development potential and patient selection and clinical trial designs. Likewise, advances in artificial intelligence and real-world data is changing the way investigators can accelerate and develop knowledge and evidence to help guide clinical decision-making and ensure the utilization of the most effective treatment for every patient.

At Cancer Research and Development Conference 2026, this session will provide insight into the most exciting and promising oncology pipeline assets and the science behind pipeline asset development. Participants will hear from a panel of experts regarding early-phase breakthroughs, regulatory pathways, and actionable items to get pre-clinical discoveries into clinical practices. The session will also feature discussions and demonstrations about new evidence and the prospective impact on next-generation drug development and movement of innovations forward into oncological research and therapeutics. Join us as we analyze the next wave of innovations that will drive our collective future of better oncology research and the therapeutic development process.